Scarica l'app Stockscreener
188.05
1.97%
-3.77
Dopo l'orario di chiusura:
188.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$191.82
Aprire:
$190.22
Volume 24 ore:
690.98K
Relative Volume:
0.39
Capitalizzazione di mercato:
$27.60B
Reddito:
$9.53B
Utile/perdita netta:
$1.29B
Rapporto P/E:
21.36
EPS:
8.8057
Flusso di cassa netto:
$1.97B
1 W Prestazione:
-4.22%
1M Prestazione:
+5.00%
6M Prestazione:
+34.68%
1 anno Prestazione:
+33.84%
Intervallo 1D:
$186.72
$190.75
Intervallo di 1 settimana:
$185.90
$198.72
Portata 52W:
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, NVS, AZN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
188.05 | 28.15B | 9.53B | 1.29B | 1.97B | 8.8057 |
|
LLY
Lilly Eli Co
|
1,017.97 | 992.40B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
248.56 | 598.69B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
234.26 | 410.36B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
166.87 | 321.75B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
203.73 | 323.26B | 58.80B | 10.24B | 8.98B | 3.2788 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-02-09 | Reiterato | H.C. Wainwright | Buy |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Downgrade | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Aggiornamento | Stifel | Hold → Buy |
| 2025-09-25 | Iniziato | Jefferies | Buy |
| 2025-07-21 | Ripresa | Truist | Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
TD Asset Management Inc Increases Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Rafferty Asset Management LLC Lowers Stake in Biogen Inc. $BIIB - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Has $43.06 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen’s BIIB080 Readout Tests Alzheimer’s Hopes And Investor Sentiment - simplywall.st
Biogen (BIIB) Receives a Buy from RBC Capital - The Globe and Mail
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Generali Investments Management Co LLC Grows Holdings in Biogen Inc. $BIIB - MarketBeat
Fox Run Management L.L.C. Has $976,000 Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Given Average Rating of "Hold" by Brokerages - MarketBeat
AMETHYST trial of litifilimab making "strong progress," Biogen says - Lupus News Today
Biogen Faces Uncertain Outlook for Alzheimer's Drug But Pipeline Supports Growth, RBC Says - marketscreener.com
Primecap Management Co. CA Has $2.09 Billion Stock Holdings in Biogen Inc. $BIIB - MarketBeat
10,006 Shares in Biogen Inc. $BIIB Acquired by K.J. Harrison & Partners Inc - MarketBeat
Biogen Stock After Alzheimer’s Shake-Up: Bargain or Value Trap? - AD HOC NEWS
Biogen to Participate in the TD Cowen 46th Annual Health Care Conference - Biogen
Here Are Thursday’s Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More - AOL.com
Dementia Treatment Market Booming with Rapid Growth Through - openPR.com
Biogen Pharmachem Industries Ltd is Rated Strong Sell - Markets Mojo
How (BIIB) Movements Inform Risk Allocation Models - Stock Traders Daily
Biogen Receives Honorable Mention From Fast Company's World Changing Ideas Awards - CSRwire
Biogen-Funded Collaboration with Americares and Harvard Chan C-CHANGE Recognized by the Clinton Global Initiative - CSRwire
Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative - CSRwire
Biogen Included in 2022 Bloomberg Gender-Equality Index - CSRwire
Skandinaviska Enskilda Banken AB publ Has $4.07 Million Position in Biogen Inc. $BIIB - MarketBeat
Barclays Upgrades Biogen (NASDAQ:BIIB) to Hold - MarketBeat
Barclays Initiates Coverage of Biogen (BIIB) with Equal-Weight Recommendation - Nasdaq
Beyond The Numbers: 21 Analysts Discuss Biogen Stock - Benzinga
Biogen’s BIIB091 MS Trial Reaches Completion, Setting Up a Key Pipeline Catalyst - TipRanks
Barclays initiates Biogen stock coverage with $185 price target By Investing.com - Investing.com Nigeria
Biogen (BIIB) Receives New Analyst Coverage with Equal-Weight Ra - GuruFocus
Barclays initiates Biogen stock coverage with $185 price target - Investing.com
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Stock Position in Biogen Inc. $BIIB - MarketBeat
New Biogen Chair Freire May Recast Partnerships And Capital Priorities - Yahoo Finance
Eisai & Biogen Canada Disagree With Canada's Drug Agency's Leqembi Reimbursement Rejection - TradingView
Eisai Maintains Commitment to People Living with Early Alzheimer's Disease Despite CDA-AMC Draft Recommendation: Patients Deserve Access to Effective Treatment - Yahoo Finance
Assessing Biogen (BIIB) Valuation As Shares Gain 18.1% In 30 Days And 42% Over One Year - Yahoo Finance
Biogen (BIIB) Valuation Check After Earnings Momentum And Analyst Optimism - simplywall.st
NEOS Investment Management LLC Boosts Position in Biogen Inc. $BIIB - MarketBeat
Multiple Sclerosis Therapeutics Market to Reach USD 46.22 - openPR.com
Aberdeen Group plc Cuts Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Alzheimer's Therapeutics Market Research Report 2026-2036: Growing Global Burden of Alzheimer's Continues to Drive Demand - GlobeNewswire Inc.
Biogen head of pharm ops Murphy buys $585 in stock By Investing.com - Investing.com Canada
Biogen head of pharm ops Murphy buys $585 in stock - Investing.com
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wedbush lifts PT on Biogen Inc. (BIIB) to $187 from $178 – here’s why - MSN
5,611 Shares in Biogen Inc. $BIIB Purchased by Caprock Group LLC - MarketBeat
Biogen Stock Performance 2026 | Financial Results & Analyst RatingsNews and Statistics - IndexBox
What Price Targets Have Wall Street Analysts Set for Biogen Shares? - Bitget
What Are Wall Street Analysts' Target Price for Biogen Stock? - Yahoo Finance
AlphaQuest LLC Sells 10,789 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.41%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):